Jupiter Neurosciences execs forgive $875K pay

JUPITER NEUROSCIENCES, INC.

Rhea-AI Filing Summary

JUPITER NEUROSCIENCES, INC. (JUNS) entered into separate Debt Forgiveness and Release Agreements on August 26, 2026 with certain executive officers and directors. These individuals irrevocably forgave an aggregate of $875,315 of accrued and unpaid compensation that had been recorded as liabilities.

The forgiven amounts included $356,024 for Chairman, Chief Executive Officer and Director Christer Rosén, $81,431 for President, Chief Operating Officer and Director Alison Silva, $287,075 for Chief Scientific Officer and Director Marshall Hayward, and $150,785 for Chief Administrative Officer Alexander Rosén. The Debt Forgiveness was gratuitous; the company did not issue equity securities or pay cash or other consideration in return. Each agreement also includes a general release of claims related to the forgiven compensation, subject to customary exceptions. As of this report date, the company has 1,318,521 shares of common stock issued and outstanding.

Positive

• $875,315 of accrued and unpaid executive and director compensation was irrevocably forgiven, eliminating that liability without any cash or equity consideration paid by the company.
• Key executives, including the CEO and other senior officers, provided a gratuitous debt forgiveness and general release of related claims, which reduces potential claims tied to these compensation obligations.

Negative

• None.

8-K Event Classification

4 items: 1.01, 5.02, 8.01, 9.01

4 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Aggregate accrued compensation forgiven: $875,315 Compensation forgiven - Christer Rosén: $356,024 Compensation forgiven - Alison Silva: $81,431 +3 more

6 metrics

Aggregate accrued compensation forgiven $875,315 Accrued and unpaid compensation irrevocably forgiven by executives and directors on August 26, 2026

Compensation forgiven - Christer Rosén $356,024 Accrued salary owed to Chairman, Chief Executive Officer and Director

Compensation forgiven - Alison Silva $81,431 Accrued salary owed to President, Chief Operating Officer and Director

Compensation forgiven - Marshall Hayward, Ph.D. $287,075 Accrued salary owed to Chief Scientific Officer and Director

Compensation forgiven - Alexander Rosén $150,785 Accrued salary owed to Chief Administrative Officer

Common shares outstanding 1,318,521 shares Common stock issued and outstanding as of the date of the report

Key Terms

Debt Forgiveness and Release Agreements, accrued and unpaid compensation, general release of claims, Emerging Growth Company

4 terms

Debt Forgiveness and Release Agreements financial

"entered into separate Debt Forgiveness and Release Agreements with certain"

accrued and unpaid compensation financial

"forgave an aggregate of $875,315 of accrued and unpaid compensation"

general release of claims regulatory

"each Forgiveness Agreement contains a general release of claims by the applicable"

Emerging Growth Company regulatory

"Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What material agreement did JUPITER NEUROSCIENCES, INC. (JUNS) enter on August 26, 2026?

JUPITER NEUROSCIENCES, INC. entered into separate Debt Forgiveness and Release Agreements with certain executive officers and directors, under which they irrevocably forgave accrued and unpaid compensation previously owed by the company.

How much executive and director compensation did JUNS have forgiven?

Executives and directors forgave an aggregate of $875,315 in accrued and unpaid compensation. These amounts had been recorded as liabilities, and the forgiveness was granted without any cash, equity securities, or other consideration from the company.

Which JUNS executives participated in the debt forgiveness and in what amounts?

Participants included Christer Rosén ($356,024), Alison Silva ($81,431), Marshall Hayward, Ph.D. ($287,075), and Alexander Rosén ($150,785), each irrevocably terminating the company’s obligations for these accrued compensation amounts.

Did JUNS issue any shares or pay cash for the debt forgiveness?

No. The company states the Debt Forgiveness was gratuitous. It did not issue any equity securities or pay any cash or other consideration in exchange for the forgiveness of the accrued compensation obligations.

How many JUNS common shares are currently outstanding?

As of the date of this report, JUPITER NEUROSCIENCES, INC. has 1,318,521 shares of common stock issued and outstanding, as disclosed in the Other Events section.

What legal protections are included in the JUNS Debt Forgiveness and Release Agreements?

Each agreement includes a general release of claims in favor of the company and its affiliates regarding claims arising out of or relating to the forgiven compensation obligations, subject to customary exceptions, including claims under the Forgiveness Agreement itself.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/27/2026 - 06:31 AM EDT Accepted by SEC EDGAR 08/27/2026 - 06:30 AM EDT Learn about SEC filing dates

false 0001679628 0001679628 2026-08-26 2026-08-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

August 26, 2026

Date of Report (Date of earliest event reported)

JUPITER NEUROSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41265		47-4828381
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

11621 Kew Gardens Ave, Suite 210, Palm Beach Gardens, FL		33410
(Address of principal executive offices)		(Zip Code)

(561) 406-6154

Registrant’s telephone number, including area code

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		JUNS		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

On August 26, 2026, Jupiter Neurosciences, Inc. (the “Company”) entered into separate Debt Forgiveness and Release Agreements (each, a “Forgiveness Agreement” and collectively, the “Forgiveness Agreements”) with certain executive officers and directors of the Company pursuant to which such individuals irrevocably forgave an aggregate of $875,315 of accrued and unpaid compensation previously owed by the Company (the “Debt Forgiveness”). The forgiven amounts consisted of accrued salaries that had been reflected as liabilities on the Company’s balance sheet.

The following table sets forth the amounts forgiven by each individual:

Name		Title		Amount Forgiven
Christer Rosén		Chairman and Chief Executive Officer and Director		$	356,024
Alison Silva		President, Chief Operating Officer and Director		$	81,431
Marshall Hayward, Ph.D.		Chief Scientific Officer and Director		$	287,075
Alexander Rosén		Chief Administrative Officer		$	150,785

Pursuant to the Forgiveness Agreements, effective as of August 26, 2026, each applicable individual agreed to irrevocably terminate and forgive in full the accrued compensation obligations owed by the Company to such individual. The Debt Forgiveness was gratuitous, and the Company did not issue any equity securities or pay any cash or other consideration in exchange for the forgiveness of such obligations. In addition, each Forgiveness Agreement contains a general release of claims by the applicable individual in favor of the Company and its affiliates and their respective officers, directors, stockholders and agents with respect to claims arising out of or relating to the forgiven compensation obligations, subject to customary exceptions, including claims arising under the Forgiveness Agreement itself.

The foregoing summary of the Forgiveness Agreements does not purport to be complete and is qualified in its entirety by reference to the form of the Forgiveness Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

Item 8.01 Other Events.

As of the date of this Current Report on Form 8-K, the Company has 1,318,521 shares of Common Stock issued and outstanding.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit No.		Description
10.1		Form of Debt Forgiveness and Release Agreement, dated as of August 26, 2026, by and between the Company and the Counterparty party thereto.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	JUPITER NEUROSCIENCES, INC.
Dated: August 27, 2026	By:	/s/ Christer Rosen
	Name:	Christer Rosen
	Title:	Chief Executive Officer

Filing Exhibits & Attachments

4 documents

Agreements & Contracts

• EX-10.1 EX-10.1 92.6 KB

Other Documents

• EX-101 XBRL SCHEMA FILE 3.0 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.9 KB